Raymond James Financial Inc. Invests $274,000 in Immunome, Inc. (NASDAQ:IMNM)

Raymond James Financial Inc. bought a new position in Immunome, Inc. (NASDAQ:IMNM) during the fourth quarter, Holdings Channel reports. The fund bought 25,817 shares of the company’s stock, valued at approximately $274,000.

A number of other institutional investors and hedge funds have also made changes to their positions in IMNM. Charles Schwab Investment Management Inc. boosted its stake in Immunome by 217.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after purchasing an additional 302,916 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Immunome by 13.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after buying an additional 144,557 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Immunome by 137.1% during the 3rd quarter. Wellington Management Group LLP now owns 140,690 shares of the company’s stock valued at $2,057,000 after purchasing an additional 81,354 shares during the period. Barclays PLC boosted its stake in shares of Immunome by 125.9% during the 3rd quarter. Barclays PLC now owns 105,886 shares of the company’s stock worth $1,547,000 after acquiring an additional 59,016 shares during the last quarter. Finally, Scharf Investments LLC purchased a new position in Immunome during the fourth quarter valued at $471,000. Institutional investors own 44.58% of the company’s stock.

Insider Buying and Selling

In other news, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction dated Monday, March 24th. The shares were purchased at an average cost of $8.21 per share, with a total value of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares of the company’s stock, valued at approximately $193,879.15. The trade was a 42.13 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Clay B. Siegall acquired 137,100 shares of the firm’s stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of $7.29 per share, for a total transaction of $999,459.00. Following the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at $5,881,105.44. This represents a 20.47 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 306,400 shares of company stock valued at $2,322,995 over the last 90 days. Insiders own 8.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on IMNM shares. Stephens restated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital initiated coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective for the company. Lake Street Capital initiated coverage on Immunome in a report on Wednesday, April 2nd. They set a “buy” rating and a $23.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Finally, Guggenheim decreased their price objective on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $25.14.

Immunome Price Performance

IMNM opened at $6.20 on Friday. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $21.72. The firm has a market capitalization of $539.10 million, a PE ratio of -0.76 and a beta of 2.05. The business’s 50-day moving average is $8.63 and its two-hundred day moving average is $10.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The company had revenue of $2.74 million for the quarter, compared to analyst estimates of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, sell-side analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.